

**84mo CONGRESSO ANNUALE
DELLA SOCIETÀ SVIZZERA DI PATOLOGIA**

**84th ANNUAL CONGRESS
OF THE SWISS SOCIETY OF PATHOLOGY**

**84. JAHRESTAGUNG DER SCHWEIZERISCHEN
GESELLSCHAFT FÜR PATHOLOGIE**

**84^e CONGRÈS ANNUEL
DE LA SOCIÉTÉ SUISSE DE PATHOLOGIE**

8-10.11.2018



**Palazzo
Congressi**
Lugano

final program

SGPath | SSPath

SOCIÉTÉ SUISSE DE PATHOLOGIE
SCHWEIZERISCHE GESELLSCHAFT FÜR PATHOLOGIE
SWISS SOCIETY OF PATHOLOGY

Online registration/Anmeldungen/Inscriptions

www.meeting-com.ch



Personalize your care for women with early breast cancer

MammaPrint and Blueprint help you and your patients make confident, informed treatment management decisions that avoid unnecessary side effects

MammaPrint's High Risk or Low Risk of recurrence result identifies patients unlikely to benefit from chemotherapy

- Backed by highest level of clinical evidence from the MINDACT Trial¹
- The device is CE-marked and FDA-cleared

Blueprint's functional molecular subtyping can identify patients who may benefit from neo-adjuvant therapy

- Superior to IHC and FISH – reclassifies 22% of tumors²
- The device is CE-marked and can be run simultaneously with MammaPrint

Almost half of clinically high risk women reclassified as Low Risk with MammaPrint¹

Find out more at
www.agendia.com

Welcome

Dear Colleagues

It is our great pleasure to welcome you to the 84th Annual Meeting of the Swiss Society of Pathology, which will be taking place for the first time in Lugano.

Pathologists are increasingly challenged with the recognition and classification of pre-invasive lesions, which are detected either by organized screening programs or by opportunistic investigations. With this in mind, we invited national and international experts to discuss our understanding of precursor lesions of various cancer types, and to improve our knowledge to recognize hereditary syndromes by morphological features or by a growing array of molecular pathology tests.


The dramatically increased demands on pathologists over the past few years reflect further our expanding role, not only in the diagnostic setting, but also, more in general, in public health and medical education. For these reasons we will have the opportunity during the meeting to expand our contacts to epidemiologists working in national tumor registries, medical geneticists with whom we share areas of interest, as well as professionals active in the design and evaluation of medical school programs.

The traditional half-day post-graduate course, preceding the main congress, will be devoted to ovarian tumors. We hope that this challenging field will be of interest not only to residents but also to board certified pathologists who are confronted with these diseases in their daily practice.

Lugano is a beautiful and attractive convention venue so, besides an interesting and educational meeting, we hope you will also have an enjoyable stay in Ticino.

We are looking forward to meeting you all in Lugano and having a great time together.

With our kind regards



Prof. Dr Luca Mazzucchelli
Congress President



Dr med. Bettina Bisig
Congress Vice President



PD Dr med. Matthias Matter
Congress Vice President

¹ Cardoso, F., et al. N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253

² Cristofanilli M, et al. Cancer Res. 2012;72(24 Suppl): Abstract nr P3-05-01

Table of content

Welcome	3
Organization	5
General information	6-7
Program at a glance	9-11
Scientific program	12-20
Speakers and chair·wo·men	22
E-Poster presentations	23-27
Exhibition	28
Sponsored lecture	29
Kind thanks to all our sponsors	30-31
Save the dates 2019 & 2020	32

Organization

Congress President	Luca Mazzucchelli, Locarno
Congress Vice Presidents	Bettina Bisig, Lausanne Matthias Matter, Basel
Organizing Committee	Milo Frattini, Locarno Alexandra Valera, Locarno Matthias Dettmer, Bern Niels Rupp, Zurich Anne-Laure Rougemont, Geneva
SGPath/SSPath Board	President Gieri Cathomas, Liestal Vice President Alessandro Lugli, Bern Secretary Zsuzsanna Varga, Zurich Administration SGPath/SSPath Alexandra Safret, Neuchâtel Quality Management Joachim Diebold, Lucerne Representative Molecular Pathology Wolfram Jochum, St. Gallen Tariff: DRG, Tarmed Philip Went, Basel Representative Cytopathology Massimo Bongiovanni, Lausanne Representative Training and continuous education Paul Komminoth, Zurich

General information

Congress venue

Palazzo dei Congressi Lugano
Piazza Indipendenza 4, 6900 Lugano
www.luganoconventions.com

Registration & Congress secretariat

Meeting.com Congress Organisation
Rue des Pâquis 1 • CP 100
CH-1033 Cheseaux-sur-Lausanne
T 021 312 92 61 • F 021 312 92 63
nicole.giacomini@meeting-com.ch



Online registration on www.meeting-com.ch
Onsite registration also possible (onsite fee)

Registration fees

HALF-DAY POST-GRADUATE COURSE FOR RESIDENTS IN TRAINING Thursday, November 8, 2018

Residents and SSPath members
Others

Early fee (before Sept 30, 2018)	Late fee & onsite (as of Oct 1, 2018)
-------------------------------------	--

☐ free of charge	☐ 130.00
☐ 100.00	

ANNUAL CONGRESS Thursday, November 8 as from 13.30 – Saturday, November 10, 2018

Residents/students/technicians
SSPath members
SSPath non-members

Early fee (before Sept 30, 2018)	Late fee & onsite (as of Oct 1, 2018)
-------------------------------------	--

☐ 150.00	☐ 200.00
☐ 250.00	☐ 280.00
☐ 290.00	☐ 320.00

GALA DINNER

Members and non-members

FRIDAY, 9.11.2018 – Hotel Splendide, Lugano
☐ 80.00 (TTC)

Payment/confirmation

After your registration/payment, you will receive our invoice/confirmation by email to the address given when registering.
Payment by credit card upon registration online is possible, as well as onsite (onsite fee).

Included in registration fee

Access to the conferences, certificate of attendance, badge, coffee breaks & lunches.

Not included in the registration fee

The Gala Dinner is not included and has to be booked separately when registering (CHF 80.00 TTC). Places are limited and a reservation is required.

Certificate of attendance The certificate of attendance will be sent by email to all participants (slide seminars included) after the event.

Cancellation

Written notification is required for all cancellations and changes. In case of cancellation 30 days prior the event, the refund of the amount paid will be done net of CH 60.00 for administrative costs. Thereafter no refund is possible. Any registration made within the “early bird” time must be paid during this period. If not the case, the invoice is automatically updated at the current price. Administrative costs will be charged to no shows. Legal jurisdiction is Lausanne.

Oral presentations

5 oral presentation sessions: on Thursday 8.11.18 (14.45 and 16.15) and on Friday 9.11.18 (09.30, 12.15 and 15.15).

E-Poster sessions

3 moderated E-poster sessions: on Thursday 8.11.18 at 15.15 and on Friday 9.11.18 at 10.00 and 15.45.

Language

The language of the congress is English.

Industrial exhibition

An industrial exhibition will take place at the Congress venue on Thursday 8.11.18 and Friday 9.11.18.

Hotel booking

Hotel reservation available on www.luganoturismo.ch

Credits

Credit points given by the Swiss Society of Pathology.

**Half-day post graduate course
for residents in training** 3 credits

Annual congress
Thursday 8.11.18 5 credits
Friday 9.11.18 8 credits
Saturday 10.11.18 5 credits
Per slide seminar +1 credit for rendering diagnoses

Internet access

SSID: PalazzoCongressi
Password: Luga2018

TEST ME for BRCAm TREAT ME with Lynparza™

Erste zielgerichtete
Erhaltungstherapie für
das Ovarialkarzinom¹

Neue Langzeitdaten²
15%* der Patientinnen für
≥5 Jahre in Behandlung



Referenzen

1. Fachinformation Lynparza™, www.swissmedicinfo.ch
 2. Ledermann J. et al. "Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: An updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial." *The Lancet Oncology*. 2016 Nov;17(11):1579-89.
- * Patientinnen mit BRCA Mutation [n=74] behandelt mit Lynparza™ versus 2% bei BRCAm Patientinnen behandelt mit Placebo [n=62]

Lynparza™

Z: Olaparibum; Kapseln zu 50 mg; Liste A, I: Zur Erhaltungstherapie (Monotherapie) bei Patientinnen mit fortgeschrittenem, rezidierten Ovarialkarzinom mit BRCA Mutation im Anschluss an eine platinhaltige Chemotherapie bei Vorliegen einer kompletten oder partiellen Remission. **D:** 400 mg zweimal täglich. Dosisanpassung auf 200 mg bzw. 100 mg zweimal täglich möglich. **KI:** Überempfindlichkeit gegenüber dem Wirkstoff oder einem der Hilfsstoffe. Schwangerschaft und Stillzeit. **V:** Hämatologische Toxizität. Myelodysplastisches Syndrom/akute myeloide Leukämie. Pneumonitis. Erhöhung des Kreatinins. Interaktionen mit starken CYP3A Induktoren od. Inhibitoren. **IA:** Starke CYP3A4/5 und P-gp Inhibitoren, CYP3A-Induktoren, Substrate von CYP3A4 und Transportern. **UAW:** Sehr häufig: Übelkeit, Erbrechen, Diarrhö, Dyspepsie, Fatigue, Kopfschmerzen, Dysgeusie, verminderter Appetit, Schwindel, Anämie, Neutropenie, Lymphopenie, Erhöhung des mittleren korpuskulären Volumens, Erhöhung des Kreatinins. Häufig: Thrombozytopenie, Stomatitis, Schmerzen im Oberbauch. Gelegentlich, selten, sehr selten: siehe www.swissmedicinfo.ch. Weitere Informationen: www.swissmedicinfo.ch oder AstraZeneca AG, 6301 Zug, www.astrazeneca.ch.



Program at a glance

Thursday, Nov. 8

From 07.30	Registration & welcome coffee	Foyer
08.30-10.30	Half-day post-graduate course for residents in training	Plenary
10.30-11.00	Coffee break	Foyer
11.00-12.00	Half-day post-graduate course for residents in training	Plenary
11.30-13.00	Welcome snack	Exhibition
13.00	Opening and welcome	
13.15-15.15	MAIN SESSION 1	Plenary
14.45-15.15	SESSION 1 3 ORAL PRESENTATIONS	
15.15-16.15	E-POSTER SESSION 1	Room C1-2
15.15-16.15	Coffee break	Exhibition
16.15-18.15	MAIN SESSION 2	Plenary
16.15-16.45	SESSION 2 3 ORAL PRESENTATIONS	
18.20-20.00	Director's conference	Room C2-3

E-poster viewing in the Room C1-2 during the whole day

Program at a glance

Friday, November 9

From 07.15	Registration & welcome coffee	Foyer & Exhibition
08.00-10.00	MAIN SESSION 3	Plenary
9.30-10.00	SESSION 3 3 ORAL PRESENTATIONS	
10.00-11.00	E-POSTER SESSION 2	Room C1-2
10.00-11.00	Coffee break	Exhibition
11.00-12.45	MAIN SESSION 4	Plenary
12.15-12.45	SESSION 4 3 ORAL PRESENTATIONS	
12.45-13.45	Lunch break	Exhibition
13.45-15.45	MAIN SESSION 5	Plenary
15.15-15.45	SESSION 5 3 ORAL PRESENTATIONS	
15.45-16.45	E-POSTER SESSION 3	Room C1-2
15.45-16.45	Coffee break	Exhibition & E-Poster viewing
16.45-18.15	GENERAL ASSEMBLY 2018 SGPATH	Plenary
19.30	GALA DINNER	Hotel Splendide, Lugano

E-poster viewing in the Room C1-2 during the whole day

Program at a glance

Saturday, November 10

From 07.15	Registration & welcome coffee	Foyer
08.15-09.15	MAIN SESSION 6	Plenary
09.15-10.45	SLIDE SEMINAR 1	Plenary
10.45-11.15	Coffee break	Foyer
11.15-11.45	MAIN SESSION 7	Plenary
11.45-13.15	SLIDE SEMINAR 2	Plenary
13.15	End of the congress	

From 07.30

Registration and welcome coffee

Foyer

08.30-10.30

HALF DAY POST-GRADUATE COURSE FOR RESIDENTS IN TRAINING

Plenary

Ovarian tumors

M. Körner, Ittigen; E. Schmöckel, Munich (DE); S. Lax, Graz (AT)

10.30-11.00

Coffee break

Foyer

11.00-12.00

HALF DAY POST-GRADUATE COURSE FOR RESIDENTS IN TRAINING

Plenary

Follow-up

11.30-13.30

Welcome snack

Exhibition

ANNUAL CONGRESS

13.00-13.15

Opening and welcome

L. Mazzucchelli, Locarno

Plenary

13.15-15.15

MAIN SESSION 1

SCREENING FOR LUNG CANCER

Chairs: A. Soltermann, Zurich; M. Rechsteiner, Zurich

Plenary

13.15-13.45

Sponsored lecture by MSD

Epidemiology of lung cancer in Switzerland

M. Lorez, Zurich



13.45-14.15

Early lesions in lung adenocarcinoma

S. Savic, Basel

14.15-14.45

Sponsored lecture by AstraZeneca

Liquid biopsy in lung cancer

U. Malapelle, Naples (IT)



14.45-15.15

3 ORAL PRESENTATIONS – SESSION 1: O 1-O 3

Plenary

O 1

Monitoring ar/ar-v7 expression in isolated ctcs of mcrpc patients during androgen deprivation therapy

Mrs. Ivana Bratic Hench¹, Mr. Luigi Costa¹, Dr. Christian Ruiz¹, Mrs. Heike Püschel¹, Dr. Jürgen Hench¹, Prof. Markus Tolnay¹, Dr. Richard Cathomas², Prof. Silke Gillessen³, Dr. Christian Rothermundt³, Dr. Tatjana Vlajnic¹, Prof. Lukas Bubendorf¹

¹University Hospital Basel, Department of Pathology, Basel, Switzerland, ²Cantonal Hospital Graubünden, Department of Oncology/Hematology, Graubünden, Chur, Switzerland, ³Cantonal Hospital St. Gallen, Department of Oncology/Hematology, St. Gallen, Switzerland

O 2

Epigenetic changes in DAXX and/or ATRX negative pancreatic neuro-endocrine tumors

Ms. Annunziata Di Domenico¹, Dr. Christodoulos Pipinikas², Dr. Cedric Simillion³, Dr. Tabea Wiedmer¹, Mr. Renaud Maire¹, Dr. Chrissie Thirlwell², Prof. Aurel Perren¹, Dr. Ilaria Marinoni¹

¹Institute of Pathology, University of Bern, Bern, Switzerland ²UCL Cancer Institute, ³Interfaculty Bioinformatics Unit, University of Bern, Bern, Switzerland

O 3

Targeted RNA-seq as a diagnostic tool for chromosomal translocation detection

Dr. Yann Christinat¹, Dr. Liza Ho¹, Dr. Nathalie Lin Marq¹, Dr. Margaret Berczy¹, Dr. Anne-Laure Rougemont¹, Prof. Thomas A. Mckee¹

¹Clinical Pathology Division, Geneva University Hospital, Geneva, Switzerland

15.15-16.15

E-POSTER SESSION 1: P 1-P 9

Room C1-2

Chairs: S. Savic, Basel; R. Sarro, Lausanne

15.15-16.15

Coffee break – Visit of the exhibition

Exhibition area

Thursday, November 8

16.15-18.15

MAIN SESSION 2

EARLY DISEASE IN MALIGNANT LYMPHOMAS

Chairs: S. Cogliatti, St. Gallen; T. McKee Geneva

Plenary

16.15-16.45

3 ORAL PRESENTATIONS – SESSION 2: O 4-O 6

Plenary

O 4

Genetic characterization of ocular adnexal lymphomas (OAL) and related entities by targeted high-throughput sequencing (HTS)

Mr. Visar Vela¹, Dr. Darius Juskevicius¹, Prof. Peter Meyer², Dr. Anne Graber³, Prof. Gieri Cathomas³, Prof. Stefan Dirnhofer¹, Prof. Alexandar Tzankov¹

¹Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland

²Eye Clinic and Institute of Medical Genetics and Pathology, University Hospital, Basel, Switzerland, ³Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland

O 5

Dealing with bone marrow infiltration by angioimmunoblastic T-cell lymphoma: morphologic patterns and ancillary diagnostic methods

Dr. Magdalena Gerlach¹, Dr. Darius Juskevicius¹, Mr. Visar Vela², Prof. Stefan Dirnhofer¹, Prof. Alexandar Tzankov¹

¹Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland, ²Institute of Pathology, University Hospital Basel, Basel, Switzerland

O 6

Keratin-7 immunoexpression in hepatocytes: synthesis of a 3 years' experience on liver biopsies

Dr. Marie Maillard¹, Dr. Amedeo Sciarra¹, Prof. Christine Sempoux¹

¹Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland

16.45-17.15

Epidemiology of malignant lymphomas in Switzerland

S. Rohrmann, Zurich

17.15-17.45

Precursor lesions and risks for malignant lymphomas

L. de Leval, Lausanne

17.45-18.15

Liquid biopsy in malignant lymphomas

D. Rossi, Bellinzona

18.20-20.00

Director's conference

Room C2-3

Friday, November 9

From 07.15

Registration and welcome coffee

Foyer & Exhibition

08.00-10.00

MAIN SESSION 3

RISK ASSESSMENT IN GASTROINTESTINAL AND LIVER PATHOLOGY

Chairs: C. Sempoux, Lausanne; H. Dawson, Bern

Plenary

08.00-08.30

Hereditary polyposis of the colon

K. Heinimann, Basel

08.30-09.00

Diagnostic dilemmas in colorectal cancer screening

N. Shepherd, Cheltenham (GB)

09.00-09.30

Precursor lesions of hepatocellular carcinoma

M. Roncalli, Milan (IT)

09.30-10.00

3 ORAL PRESENTATIONS – SESSION 3: O 7-O 9

Plenary

O 7

miR-579-3p controls hepatocellular carcinoma formation by regulating the PI3K-AKT pathway in chronically inflamed liver

Dr. Cristina Quintavalle¹, Dr. Stephanie Roessler², Dr. Diego Calabrese³, Dr. Romina Marone⁴, Dr. Katharina Burmeister¹, Dr. Silvia Picco-Rey¹, Dr. Orestis Panagiotou⁵, Dr. Luca Quagliata¹, Dr. Salvatore Piscuoglio¹, Dr. Tuyana Boldanova³, Chaoran Bian⁶, Dr. David Semela⁷, Prof. Wolfram Jochum⁸, Prof. Gieri Cathomas⁹, Dr. Kirsten D. Mertz⁹, Dr. Viktor Koelzer⁹, Prof. Joachim Diebold¹⁰, Prof. Luca Mazzucchelli¹¹, Prof. Achim Weber¹², Prof. Thomas Decaens¹³, Prof. Luigi Terracciano¹, Prof. Yujin Hoshida¹⁴, Prof. Jesper Andersen¹⁵, Dr. Snorri Thorgeirsson¹⁶ and Dr. Matthias Matter¹

¹Institute of Medical Genetics and Pathology, University Hospital Basel, Switzerland,

²Institute of Pathology, University Hospital Heidelberg, Germany, ³Division of Hepatology and Gastroenterology, University Hospital of Basel, Switzerland,

⁴Department of Biomedicine, University of Basel, Switzerland, ⁵Brown University School of Public Health, USA, ⁶Icahn School of Medicine at Mount Sinai, USA, ⁷Division of Gastroenterology, Kantonsspital St. Gallen, Switzerland, ⁸Institute of Pathology, Kantonsspital St. Gallen, Switzerland, ⁹Institute of Pathology, Kantonsspital Baselland, Switzerland, ¹⁰Institute of Pathology, Luzerner Kantonsspital, Switzerland, ¹¹Istituto Cantonale di Patologia, Locarno, Switzerland, ¹²Institute of Pathology, University Hospital of Zurich, Switzerland, ¹³Institute for Advanced Biosciences, Grenoble, France, ¹⁴University of Texas Southwestern Medical Center, USA, ¹⁵Biotech Research and Innovation Centre, Copenhagen, Denmark, ¹⁶National Cancer Institute, Bethesda, USA

O 8

Intratumor heterogeneity and alternative driver mutations in HER2 positive gastric cancers

Ms. Jacqueline Ritz¹, Dr. Ronny Nienhold¹, Ms. Angela Frank¹, Ms. Patricia Thommen¹, Ms. Melanie Sachs¹, Dr. Bastian Dislich², Prof. Rupert Langer², Prof. Felix Offner³, Prof. Holger Moch⁴, Prof. Joachim Diebold⁵, Prof. Gieri Cathomas¹

¹Institut für Pathologie, Kantonsspital Baselland, Liestal, Switzerland ²Institute of Pathology, University of Bern, Bern, Switzerland ³Institut für Pathologie, Landeskrankenhaus Feldkirch, Austria ⁴University Hospital Zurich, Department of Pathology, Zurich, Switzerland ⁵Institute of Pathology, Kantonsspital Luzern, Luzern, Switzerland

O 9

Tumor Budding and the Consensus Molecular Subtypes (CMS) in Colorectal Cancer: Association with the Mesenchymal CMS4 Subtype

Prof. Inti Zlobec¹, Dr. Anne Trinh², Dr. Claudia Ladrach³, Dr. Heather Dawson³, Ms. Sanne Ten Hoorn⁴, Prof. Alessandro Lugli⁵, Prof. Louis Vermeulen⁴

¹University of Bern, Bern, Switzerland, ²Dana-Farber Cancer Institute, Boston, USA ³University of Bern, Institute of Pathology, Bern, Switzerland ⁴Amsterdam Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Institute of Pathology, University of Bern, Bern, Switzerland

10.00-11.00

E-POSTER SESSION 2: P 10-P 17

Room C1-2

Chairs: A. Tzankov, Basel; M. Frattini, Locarno

10.00-11.00

Coffee break - Visit of the exhibition

Exhibition area

11.00-12.45

MAIN SESSION 4

KEYNOTE LECTURE

Plenary

Chairs: G. Cathomas, Liestal; K. Glatz, Basel

11.00-11.45

Teaching at medical schools: current challenges and difficulties

W. Georg, Zurich

11.45-12.15

Sponsored symposium by Promega

Microsatellite instability testing as a tool for personalized medicine

W. Jochum, St. Gallen



12.15-12.45

3 ORAL PRESENTATIONS – SESSION 4: O 10-O 12

Plenary

O 10

Microfluidic-based Immunohistochemistry for Molecular Profiling of Breast Cancer: a Comparative Clinical Study

Dr. Fabio Aimi¹, Ms. Maria Teresa Alvares Flores², Dr. Maria Giuseppina Procopio³, Dr. Nathalie Piazzon², Dr. Saska Brajkovic⁴, Dr. Diego Dupouy⁴, Prof. Martin Gijs¹, Prof. Laurence De Leval²

¹Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland, ²CHUV, Lausanne, Switzerland ³University Hospital Zurich, Department of Pathology, Zurich, Switzerland, ⁴Lunaphore Technologies SA, Lausanne, Switzerland

O 11

Comparison between the Bethesda and Hamelin panel for the analysis of microsatellite instability in colorectal cancer patients

Dr. Giulia Ramelli¹, Mrs. Giorgia Senesi¹, Dr. Michael Boergesen², Dr. Rasmus Koefoed Petersen², Dr. Cecilia Caprera³, Mr. Matteo Corsi⁴, Ms. Federica Perillo¹, Dr. Paolo Spina¹, Prof. Luca Mazzucchelli¹, Dr. Ulf Bech Christensen², Dr. Milo Frattini¹

¹Institute of Pathology, Locarno, Switzerland ²PentaBase Aps, Odense, Denmark, ³University of Perugia, Institute of Pathologic Anatomy "Santa-Maria", Perugia, Italy, ⁴University of Perugia, Institute of Pathologic Anatomy "Santa-Maria", Perugia, Italy

O 12

A fast, reliable and efficient approach for molecular brain tumor routine diagnostics

Dr. Juergen Hench¹, Dr. Michel Bihl¹, Dr. Ivana Bratic Hench¹, Dr. Per Hoffmann¹, Prof. Markus Tolnay¹, Mrs. Nemya Bösch Al Jadooa¹, Prof. Luigi Mariani², Prof. David Capper³, Prof. Stephan Frank¹

¹Institut für Med. Genetik & Pathologie, USB, Basel, Switzerland, ²Universitätsspital Basel, Abt. Neurochirurgie, Basel, Switzerland ³Charité – Universitätsmedizin Berlin, Neuropathology, Berlin Germany

12.45-13.45

Lunch break – Visit of the exhibition – E-Poster viewing

Exhibition & E-Poster area

13.45-15.45

MAIN SESSION 5

MELANOMA

Chairs: R. Panizzon, Lausanne; J.A. Lobrinus, Geneva

Plenary

13.45-14.15

The dysplastic nevus conundrum

D. Massi, Florence (IT)

14.15-14.45

Epidemiology and prevention of malignant melanoma

J.-L. Bulliard, Lausanne

14.45-15.15

Sponsored lecture by Roche

Molecular genetics of malignant melanoma

A. de la Fouchardière, Lyon (FR)



15.15-15.45

3 ORAL PRESENTATIONS - SESSION 5: O 13-O 15

Plenary

O 13

CODEX: rapid, highly multiplexed fluorescence microscopy of frozen and FFPE tissues with 50+ antibodies

Dr. Christian Schürch¹, Dr. Darci Phillips², Mr. Graham Barlow¹, Mr. Salil Bhate¹, Dr. Nikolay Samusik¹, Dr. Yury Goltsev¹, Prof. Garry Nolan¹

¹Stanford University School of Medicine, Stanford, USA ²Stanford University School of Medicine, Stanford, USA

O 14

Characterization of CD73 protein expression in thyroid neoplasms

Dr. Amedeo Sciarra¹, Dr. Ines Monteiro¹, Prof. Christine Sempoux¹, Prof. Laurence De Leval¹

¹Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland

O 15

HNF1-β is a sensitive and specific marker for yolk sac tumor: a tissue microarray analysis of 607 testicular germ cell tumors

Mrs. Alessandra Gallo¹, Dr. Christian Fankhauser², Prof. Jörg Beyer³, Dr. Thomas Herrmanns², Prof. Holger Moch¹, Dr. Peter Bode²

¹University Hospital Zurich, Department of Pathology, Zurich, Switzerland,

²University of Zurich, Zurich, Switzerland, ³University of Bern, Bern, Switzerland

15.45-16.45

E-POSTER SESSION 3: P 18-P 25

Chairs: M. Roessle, Chur; P. Komminoth, Zurich

Room C1-2

15.45-16.45

Coffee break - Visit of the exhibition

Exhibition area

16.45-18.15

GENERAL ASSEMBLY 2018 SGPATH

Plenary

19.30

Gala Dinner & Award Ceremony

Hotel Splendide, Lugano

From 07.15

Registration and welcome coffee

Foyer

08.15-09.15

MAIN SESSION 6

UNIVERSAL SCREENING FOR CANCER?

Chairs: A.-L. Rougemont-Pidoux, Geneva; B. Bisig, Lausanne

Plenary

08.15-08.45

Screening for hereditary breast cancer

P.J. van Diest, Utrecht (NL)

08.45-09.15

Hereditary endometrial and colonic cancer/universal screening

M.G. Tibiletti, Varese (IT)

09.15-10.45

SLIDE SEMINAR 1

Recognizing hereditary diseases Part I

*A. de la Fouchardière, Lyon (FR); C. Sempoux, Lausanne; L. Mazzucchelli, Locarno;
A.-L. Rougemont-Pidoux, Geneva; C. Gengler, Lausanne*

Plenary

10.45-11.15

Coffee break

Foyer

11.15-11.45

MAIN SESSION 7

GENETICS AND PATHOLOGY

Chairs: M. Matter, Basel; D. Baumhoer, Basel

Plenary

11.15-11.45

Legal and ethical issues related to screening for hereditary cancer syndromes

A. Rauch, Zurich

11.45-13.15

SLIDE SEMINAR 2

Recognizing hereditary diseases Part II

M. Dettmer, Bern; Niels Rupp, Zurich; Sylvia Hoeller, Basel; D. Baumhoer, Basel

Plenary

13.15

End of the congress



VENTANA DP 200 slide scanner

Fast and simple

High speed scanning with a no-touch start process and intuitive user interface

Robust and reliable

Automatic calibrations and built-in diagnostics produce high-quality images

Flexible and versatile

Designed and suitable for a variety of applications

- **High-quality images:** outstanding images for various tissue types, including challenging slides and frozen sections
- **DICOM compatibility:** provide a standardized output file format for interoperability with PACS servers
- **Color management:** ICC color profile applied to every scanned image
- **Dynamic focus:** tracks tissue depth in real-time and uses the data for high-resolution images
- **No slide handling:** the tray-based system to load slides for scanning eliminates slide handling errors and improves reliability

© 2018 Roche

Roche Diagnostics (Switzerland) Ltd · 6343 Rotkreuz · E-Mail info.rdch@roche.com · Phone +41 41 799 61 00
www.roche-diagnostics.ch

Speakers and chair·wo·men

BAUMHOER Daniel Basel

BISIG Bettina Lausanne

BULLIARD Jean-Luc Lausanne

CATHOMAS Gieri Liestal

COGLIATTI Sergio St. Gallen

DAWSON Heather Bern

DE LA FOUCHARDIÈRE Arnaud
Lyon (FR)

DE LEVAL Laurence Lausanne

DETTMER Matthias Bern

FRATTINI Milo Locarno

GENGLER Carole Lausanne

GEORG Waltraud Zurich

GLATZ Kathrin Basel

HEINIMANN Karl Basel

HOELLER Sylvia Basel

JOCHUM Wolfram St.Gallen

KOERNER Meike Ittigen

KOMMINOTH Paul Zurich

LAX Sigurd Graz (AT)

LOBRINUS J. Alexandre Geneva

LOREZ Matthias Zurich

MALAPELLE Umberto Naples (IT)

MASSI Daniela Florence (IT)

MATTER Matthias Basel

MAZZUCHELLI Luca Locarno

MCKEE Thomas Geneva

PANIZZON Renato Lausanne

RAUCH Anita Zurich

RECHSTEINER Markus Zurich

ROHRMANN Sabine Zurich

RONCALLI Massimo
Rozzano - Milano (IT)

ROSSI Davide Bellinzona

RÖSSLE Matthias Chur

ROUGEMONT-PIDOUX Anne-Laure
Geneva

RUPP Niels Zurich

SARRO Rossella Lausanne

SAVIC Spasenija Basel

SCHMÖCKEL Elisa Munich (DE)

SEMPOUX Christine Lausanne

SHEPHERD Neil Cheltenham (GB)

SOLTERMANN Alex Zurich

TIBILETTI Maria Grazia Varese (IT)

TZANKOV Alexandar Basel

VAN DIEST Paul J. Utrecht (NL)

E-Poster presentations

P 1

Microfluidic-based Multiplexed Immunohistochemistry for PD-L1 and p40/TTF1 on Non-Small Cell Lung Carcinoma

Dr. Maria Giuseppina Procopio¹, Dr. Saska Brajkovic², Dr. Anne-laure Leblond¹, Dr. Diego Dupouy², Prof. Alex Soltermann¹

¹University Hospital Zurich, Department of Pathology, Zurich, Switzerland,

²Lunaphore Technologies SA, Lausanne, Switzerland

P 2

Quality indicators for lung cancer care in canton Ticino (southern Switzerland), 2015-2016

Ms. Laura Ortelli¹, Dr. Alessandra Spitale¹, Ms. Paola Mazzola¹, Mrs. Simona Peverelli¹, Dr. Andrea Bordoni¹

¹Institute of Pathology, Ticino Cancer Registry, Locarno, Switzerland

P 3

ALK-STRN Fusion in a Malignant Peritoneal Mesothelioma

Dr. Jan H. Rüschoff¹, Dr. Elise Gradhand², Dr. Alessandra Curioni³, Dr. Abdullah Kahraman¹, Dr. Martin Zoche¹, Dr. Bart Vrugt¹

¹Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland, ²Paediatric & Perinatal Pathology, University Hospital Bristol, Bristol, South West England ³Department of Medical Oncology, University Hospital Zurich, Zurich, Switzerland

P 4

Identification of morphologic parameters affecting the prognosis of lung squamous cell carcinoma patients by quantitative pathology

Dr. Ruben Casanova¹, Dr. Anne-laure Leblond¹, Ms. Martina Haberecker¹, Prof. Holger Moch¹, Prof. Rolf Stahel², Dr. Irene Burger², Prof. Alex Soltermann¹

¹University Hospital Zurich, Department of Pathology, Zurich, Switzerland, ²University Hospital Zurich, Zurich, Switzerland

P 5

Comprehensive molecular dissection of pulmonary adenosquamous carcinoma

Mr. Arthur Krause¹, Dr. Salvatore Piscuoglio¹, Dr. Charlotte Ng¹, Dr. Maria Rosaria De Filippo¹, Dr. Thomas Lorber¹, Dr. Spasenija Savic¹, Prof. Lukas Bubendorf¹

¹Institute of Pathology, University Hospital Basel, Basel, Switzerland

P 6

Implementation of a next-generation sequencing bioinformatics pipeline in HUG Molecular Pathology

Dr. Yann Christinat¹, Dr. Robin Liechti², Ms. Lou Götz², Ms. Valérie Barbié², Prof. Thomas A. McKee¹

¹Clinical Pathology Division, Geneva University Hospital, Geneva, Switzerland,

²Swiss Institute of Bioinformatics, Lausanne, Switzerland

P 7

Copy Number Variation analysis in personalized medicine

Dr. Liza Ho¹, Dr. Sophie Clément¹, Dr. Yann Christinat¹, Dr. Anne-laure Rougemont¹, Prof. Thomas McKee¹

¹Clinical Pathology Division, Geneva University Hospital, Geneva, Switzerland

P 8

Can RNA expression analysis help with routine diffuse large B cell lymphoma diagnosis?

Mr. Damien Fonteneau¹, Dr. Yann Christinat¹, Dr. Liza Ho¹, Dr. Ana Avram¹, Dr. Mario Kreutzfeld¹, Dr. Margaret Berczy¹, Dr. Anne-laure Rougemont¹, Prof. Thomas McKee¹

¹Clinical Pathology Division, Geneva University Hospital, Geneva, Switzerland

P 9

T-lymphoblastic lymphoma after previous thymoma: how NGS helps establishing the diagnosis and procures new insights

Dr. Quentin Le Clef¹, Dr. Guacimara Ortega-Sanchez², Prof. Stefan Dirnhofer³, Prof. Alexandar Tzankov³

¹Department of Pathology, Maastricht University Medical Center, Maastricht, Netherlands, ²Department of Oncology, University Hospital Basel, Basel, Switzerland, ³Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland

P 10

Development of a faster and reproducible assay for microsatellite instability analysis (Bethesda panel)

Dr. Giulia Ramelli¹, Dr. Michael Boergesen², Dr. Rasmus Koefoed Petersen², Dr. Cecilia Caprera³, Mr. Matteo Corsi⁴, Ms. Federica Perillo¹, Dr. Paolo Spina¹, Prof. Luca Mazzucchelli¹, Dr. Ulf Bech Christensen², Dr. Milo Frattini¹

¹Institute of Pathology, Locarno, Switzerland ²PentaBase Aps, Odense, Denmark,

³University of Perugia, Institute of Pathologic Anatomy "Santa-Maria", Perugia, Italy

⁴University of Perugia, Institute of Pathologic Anatomy "Santa-Maria", Perugia, Italy

P 11

Tumor Budding/T-cell infiltrates in Colorectal Cancer: Proposal of a Novel Combined Score

Dr. Heather Dawson¹, Ms. Lucine Christe², Mr. Micha Eichmann², Mr. Stefan Reinhard², Prof. Inti Zlobec¹, Dr. Annika Blank², Prof. Alessandro Lugli²

¹University of Bern, Bern, Switzerland, ²Institute of Pathology, University of Bern, Bern, Switzerland

P 12

Validation of the International Tumor Budding Consensus Conference (ITBCC 2016) recommendations on tumor budding in Stage I-IV colorectal cancer

Dr. Heather Dawson¹, Dr. Francesca Galuppini², Mr. Peter Träger³, Dr. Martin D Berger⁴, Prof. Inti Zlobec¹, Dr. Peter Studer⁴, Dr. Lukas Brügger⁴, Prof. Daniel Inderbitzin⁵, Prof. Alessandro Lugli¹

¹Institute of Pathology, University of Bern, Bern, Switzerland ²University of Padova, Padova, Italy ³Careanaesth AG, Zurich, Switzerland, ⁴Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, ⁵Bürgerspital Solothurn, Solothurn, Switzerland

P 13

PDGFRA alteration in a mesenchymal tumour of the GI tract... not always a GIST

Dr. Caterina Rebecchini¹, Dr. Rossella Sarro¹, Prof. Maurice Matter², Dr. Bettina Bisig¹, Dr. Igor Letovanec¹

¹Service of Clinical Pathology, Institute of pathology, Lausanne University Hospital, Lausanne, Switzerland, ²Service of Visceral Surgery, Lausanne University Hospital, Lausanne, Switzerland

P 14

Introducing automatisisation to routine NGS diagnostics: Streamlining the Ion Torrent workflows using the Tecan liquid handler

Dr. Nadejda Valtcheva¹, Dr. Markus Rechsteiner¹

¹University Hospital Zurich, Department of Pathology, Zurich, Switzerland

P 15

Exploring neuronal diversity in archived post-mortem human brain by single-nucleus RNA sequencing

Dr. Kristof Egervari¹, Dr. Jan Broder Engler², Dr. Yann Christinat¹, Dr. Karin Steinbach³, Dr. Nicolas Page³, Ms. Ilana Vincenti³, Dr. Giovanni Di Liberto³, Ms. Bogna Klimek³, Dr. Mario Kreutzfeld¹, Mr. Karim Hammad³, Ms. Ingrid Wagner³, Prof. Thomas McKee¹, Prof. Manuel Friesen², Prof. Doron Merkler¹

¹Clinical Pathology Division; Geneva University Hospital, Geneva, Switzerland, ²Institute of Neuroimmunology and Multiple Sclerosis; University Medical Centre Hamburg, Hamburg, Germany, ³Department of Pathology and Immunology; University of Geneva, Geneva, Switzerland

P 16

Statin-induced autoimmune myopathy: unusual presentation and fatal outcome of a rare side effect

Dr. Kristof Egervari¹, Dr. Aurélie Bornand¹, Dr. Julien Lecluse², Dr. Marine Baumberger², Dr. Virginie Prendki², Dr. Johannes Alexander Lobrinus¹

¹Clinical Pathology Division; Geneva University Hospital, Geneva, Switzerland,

²Service of Internal Medicine and Rehabilitation Trois-Chêne; Geneva University Hospital, Geneva, Switzerland

P 17

Histological and molecular characterization of TFEB rearranged renal cell carcinomas

Dr. Nicolas Wyvekens¹, Dr. Markus Rechsteiner¹, Dr. Christine Fritz¹, Dr. Ulrich Wagner¹, Mrs. Carina Wenzel², Dr. Friederike Kuithan², Prof. Lars-christian Horn³, Prof. Holger Moch¹

¹University Hospital Zurich, Department of Pathology, Zurich, Switzerland, ²Institute of Pathology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ³Institute of Pathology, University Hospital Leipzig, Leipzig, Germany

P 18

Implementation of the 2018 ASCO-CAP HER2 guidelines will reduce false positive tests

Dr. Vittoria Martin¹, Dr. Alexandra Valera¹, Mrs. Melissa De Joffrey¹, Mrs. Sara Banfi¹, Prof. Luca Mazzucchelli¹

¹Institute of Pathology, Locarno, Switzerland

P 19

Pleomorphic Adenoma of the Breast – a rare breast lesion with differential diagnostic challenges

Dr. Linda Moskovszky¹, Dr. Ann-katrin Rodewald¹, Dr. Niels J. Rupp¹, Dr. Heike Frauchiger-heuer², Dr. Matthias Choschick¹, Prof. Zsuzsanna Varga¹

¹Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland, ²Department of Gynecology and Breast Cancer Center, University Hospital Zurich, Zurich, Switzerland

P 20

Immunohistochemistry for ARID1A as a urine cytology biomarker in bladder cancer

Ms. Sarah Dugas¹, Dr. David Müller¹, Dr. Clementine Le Magnen¹, Dr. Hans-Helge Seifert², Dr. Christian Ruiz¹, Dr. Tatjana Vlajnic¹, Dr. Cyrill Rentsch², Prof. Lukas Bubendorf¹

¹University Hospital Basel, Department of Pathology, Basel, Switzerland, ²University Hospital Basel, Department of Urology, Basel, Switzerland

P 21

Next generation sequencing as a tool to unravel ovarian serous cancer

Dr. Indrani Sen¹, Mr. Uwe Rogel², Ms. Karoline Sromek¹, Prof. Gad Singer¹

¹Institute of pathology, Kantonsspital Baden, Baden, Switzerland, ²Institute of Pathology, Kantonsspital Baden, Baden, Switzerland

P 22

Pembrolizumab-related adrenalitis: a case of severe immunotherapy-induced primary adrenal failure

Dr. Marie Maillard¹, Prof. Nicolo Riggi², Dr. Samuel Rotman¹

¹Service of Clinical Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland, ²Department of Experimental Pathology, Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland

P 23

A rare pediatric case of primary renal sclerosing epithelioid fibrosarcoma

Dr. Estelle Dubruc¹, Dr. Cécile Adam¹, Dr. Bettina Bisig¹, Dr. Carole Gengler¹

¹CHUV, Lausanne, Switzerland

P 24

Coronary heart disease and an incidental parathyroid carcinoma

Dr. Melanie Stoll¹, Dr. Christian Nebiker¹, Prof. Luca Remonda¹, Prof. Rainer Grobholz¹

¹Kantonsspital Aarau, Aarau, Switzerland


P 25

A comparative study on digitalisation of histopathology slides and survey on perception of the digital future

Ms. Julia Unternaehrer¹, Mr. Stefan Reinhard², Ms. Therese Waldburger¹, Dr. Ekkehard Hewer¹, Prof. Inti Zlobec³

¹University of Bern, Institute of Pathology, Bern, Switzerland, ²Institute of Pathology, University of Bern, Bern, Switzerland, ³University of Bern, Bern, Switzerland

Exhibition



- | | |
|---------------------------|---------------------------|
| 1. & 2. PHILIPS | 13. HISTOCOM |
| 3. BASYS DATA | 14. SYSMEX |
| 4. MEDITE | 15. UNILABS |
| 5. CARL ZEISS | 16. OLYMPUS |
| 6. AXON LAB | 17. BÜHLMANN LABORATOIRES |
| 7. ENZO | 18. BIOCARDIS |
| 8. SYNLAB | 19. SOPHIA GENETICS |
| 9. BIOSYSTEMS SWITZERLAND | 20. RUWAG |
| 10. ROCHE DIAGNOSTICS | 21. ADIPOGEN |
| 11. NEO GENOMICS | 22. LUNAPHORE |
| 12. PROMEGA | |

Sponsored symposium and lectures

Sponsored symposium



Sponsored lectures




Il s'agit d'un soutien d'une session de 30 minutes sur la base du programme scientifique, le sponsor n'a pas d'influence ni sur le contenu ni sur le choix de l'orateur (responsabilité de la SGPath).

Es handelt sich um eine finanzielle Unterstützung für einen 30-minütigen Vortrag auf der Grundlage des wissenschaftlichen Programms.
Der Sponsor hat keinerlei Einfluss auf den Inhalt oder auf die Wahl des Referenten, dieses obliegt alleine der SGPath.

It is a financial support of a 30-minute session based on the scientific program, the sponsor has no influence on the content, nor on the choice of the speaker (responsibility of the SGPath).

Kind thanks to all our sponsors



Save the dates

2019

4th JOINT ANNUAL MEETING of the Swiss and Austrian Societies of Pathology

and the

85th ANNUAL CONGRESS of the Swiss Society of Pathology

Thursday 7 – Friday 8 – Saturday 9 November 2019

Kultur- und Kongresszentrum, KKL LUCERNE
Europaplatz 1, CH-6005 Lucerne
www.kkl-luzern.ch

2020

86th ANNUAL CONGRESS of the Swiss Society of Pathology

Thursday 12 – Friday 13 – Saturday 14 November 2020

Kultur & Kongresshaus Aarau
Schlossplatz 9, CH-5000 Aarau
www.kuk-aarau.ch